Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $11.88 million. The enterprise value is $11.76 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 11.65 million shares outstanding. The number of shares has increased by 84.40% in one year.
| Current Share Class | 11.65M |
| Shares Outstanding | 11.65M |
| Shares Change (YoY) | +84.40% |
| Shares Change (QoQ) | +8.24% |
| Owned by Insiders (%) | 10.68% |
| Owned by Institutions (%) | 5.49% |
| Float | 7.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.29 |
| Forward PS | 0.25 |
| PB Ratio | 1.14 |
| P/TBV Ratio | 1.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 0.59.
| Current Ratio | 1.52 |
| Quick Ratio | 1.31 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -25.11 |
Financial Efficiency
Return on equity (ROE) is -141.30% and return on invested capital (ROIC) is -54.57%.
| Return on Equity (ROE) | -141.30% |
| Return on Assets (ROA) | -28.00% |
| Return on Invested Capital (ROIC) | -54.57% |
| Return on Capital Employed (ROCE) | -68.08% |
| Weighted Average Cost of Capital (WACC) | 7.12% |
| Revenue Per Employee | $443,670 |
| Profits Per Employee | -$112,085 |
| Employee Count | 94 |
| Asset Turnover | 1.65 |
| Inventory Turnover | 2.72 |
Taxes
In the past 12 months, Biofrontera has paid $25,000 in taxes.
| Income Tax | 25,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.26% in the last 52 weeks. The beta is 0.64, so Biofrontera's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | +38.26% |
| 50-Day Moving Average | 0.88 |
| 200-Day Moving Average | 0.89 |
| Relative Strength Index (RSI) | 66.54 |
| Average Volume (20 Days) | 128,425 |
Short Selling Information
The latest short interest is 295,934, so 2.54% of the outstanding shares have been sold short.
| Short Interest | 295,934 |
| Short Previous Month | 174,589 |
| Short % of Shares Out | 2.54% |
| Short % of Float | 3.72% |
| Short Ratio (days to cover) | 1.14 |
Income Statement
In the last 12 months, Biofrontera had revenue of $41.71 million and -$10.54 million in losses. Loss per share was -$1.04.
| Revenue | 41.71M |
| Gross Profit | 30.74M |
| Operating Income | -11.35M |
| Pretax Income | -10.51M |
| Net Income | -10.54M |
| EBITDA | -11.21M |
| EBIT | -11.35M |
| Loss Per Share | -$1.04 |
Full Income StatementBalance Sheet
The company has $6.40 million in cash and $6.16 million in debt, with a net cash position of $240,000 or $0.02 per share.
| Cash & Cash Equivalents | 6.40M |
| Total Debt | 6.16M |
| Net Cash | 240,000 |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | 10.48M |
| Book Value Per Share | 0.90 |
| Working Capital | 6.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.36 million and capital expenditures -$2,000, giving a free cash flow of -$13.36 million.
| Operating Cash Flow | -13.36M |
| Capital Expenditures | -2,000 |
| Depreciation & Amortization | 138,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -13.36M |
| FCF Per Share | -$1.15 |
Full Cash Flow StatementMargins
Gross margin is 73.71%, with operating and profit margins of -27.21% and -25.26%.
| Gross Margin | 73.71% |
| Operating Margin | -27.21% |
| Pretax Margin | -25.20% |
| Profit Margin | -25.26% |
| EBITDA Margin | -26.88% |
| EBIT Margin | -27.21% |
| FCF Margin | n/a |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -84.40% |
| Shareholder Yield | -84.40% |
| Earnings Yield | -87.82% |
| FCF Yield | -111.38% |
Analyst Forecast
The average price target for Biofrontera is $2.75, which is 169.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.75 |
| Price Target Difference | 169.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 18.41% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Biofrontera has an Altman Z-Score of -5.58 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.58 |
| Piotroski F-Score | 2 |
